Respiratory syncytial virus is common but it can be dangerous for some infants and young kids. Here's everything parents need ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a quiet update ...

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.

Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

The U.S. CDC recommends RSV vaccines for high-risk adults aged 50-59, endorsing the views of the former vaccine advisory ...

Merck & Co., Inc. (NYSE: MRK) is one of the. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for ...

Two panel members still voted against it, however. RSV infects nearly everyone by the time they’re 2. It causes cold symptoms, affecting the breathing passages and lungs, according to the CDC.